8-K: Aquestive Therapeutics Announces Positive Topline Results for Anaphylm Oral Allergy Syndrome Study

Aquestive Therapeutics' Anaphylm sublingual film demonstrated positive topline results in an oral allergy syndrome challenge study, showing rapid symptom resolution and consistent pharmacokinetic profiles.

Summary

• Aquestive Therapeutics announced positive topline results from its Oral Allergy Syndrome (OAS) challenge study for Anaphylm (epinephrine) Sublingual Film.
• The study met both primary and secondary endpoints, demonstrating the effectiveness of Anaphylm in resolving allergen-related symptoms.
• Symptom resolution began as early as two minutes after administration, with a median time to complete resolution of twelve minutes, compared to seventy-four minutes without the treatment.
• The pharmacokinetic (PK) profile of Anaphylm remained consistent, with no significant differences observed between subjects with and without allergen exposure.
• The time to maximum plasma concentration (Tmax) was twelve minutes for both groups, and the maximum plasma concentration (Cmax) was comparable.
• Anaphylm was well-tolerated, with all adverse events categorized as mild or moderate and resolving without medical intervention.
• The company is on track for a pre-NDA meeting with the FDA in Q4 2024 and plans to submit a New Drug Application (NDA) in Q1 2025.
• A pediatric study is also planned to commence in Q4 2024, and a full product launch is anticipated in Q1 2026 if approved by the FDA.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for Anaphylm, with rapid symptom relief and a consistent PK profile. The company is on track with its regulatory timeline, and the potential for a new, non-invasive epinephrine treatment is promising. However, there are still risks associated with regulatory approval and commercialization.

Positives

• Anaphylm demonstrated rapid symptom relief, with resolution starting as early as two minutes.
• The median time to complete symptom resolution was significantly faster with Anaphylm (12 minutes) compared to without treatment (74 minutes).
• The PK profile of Anaphylm remained consistent even with allergen exposure.
• The drug was well-tolerated, with only mild or moderate adverse events.
• The study results support the potential of Anaphylm as a reliable alternative to existing epinephrine treatments.
• The company is on track with its regulatory timeline, including a pre-NDA meeting and planned NDA submission.

Negatives

• Some subjects experienced mild palpitations as a treatment-emergent adverse event.
• A small percentage of subjects experienced nausea or vomiting.

Risks

• There are risks associated with the development and regulatory approval process, including potential delays or changes to timelines and costs.
• The FDA may require additional clinical studies for approval of Anaphylm.
• There are risks inherent in commercializing a new product, including technology, financial, market, and implementation risks.
• The company faces risks related to sufficient capital and cash resources to fund development and commercialization activities.
• There is a risk of eroding market share for Suboxone, which is a significant source of current revenue.
• The company faces risks related to competing products, including generics.
• There are risks related to intellectual property rights and potential infringement claims.
• The company is subject to risks related to legislation, regulatory actions, and changes in laws.
• There are risks related to cybersecurity attacks and disruptions to information technology networks.

Future Outlook

Aquestive is focused on advancing Anaphylm through the regulatory process, including a pre-NDA meeting with the FDA in Q4 2024, an NDA submission in Q1 2025, and a potential product launch in Q1 2026, pending FDA approval. The company also plans to commence a pediatric study in Q4 2024.

Management Comments

• Daniel Barber, President and CEO, stated that the results validate Anaphylm's potential as a game-changing treatment option for severe allergic reactions.
• Jay Lieberman, M.D., noted that the speed of symptom relief and consistent absorption profile of Anaphylm are reassuring and provide strong evidence for its potential as a reliable alternative to existing epinephrine devices.

Industry Context

This announcement is significant in the context of the epinephrine market, as Anaphylm aims to be the first non-invasive, orally delivered epinephrine for severe allergic reactions. This could disrupt the current market dominated by injectable epinephrine devices, offering a more convenient and patient-friendly alternative.

Comparison to Industry Standards

• The study compared Anaphylm's performance to intramuscular (IM) epinephrine injections, a standard treatment for anaphylaxis.
• Anaphylm demonstrated comparable or better pharmacokinetic profiles than IM injections, particularly in the early absorption phase.
• The rapid symptom resolution observed with Anaphylm is a key differentiator compared to traditional epinephrine delivery methods.
• The sublingual film delivery method offers a potential advantage over injectable epinephrine in terms of ease of use and patient acceptance.
• The study results suggest that Anaphylm could be a competitive alternative to existing epinephrine auto-injectors like EpiPen and Auvi-Q, which are the current market leaders.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the potential for a new product launch.
• Patients with severe allergies could benefit from a new, non-invasive treatment option.
• Employees may be impacted by the company's growth and development activities.
• The company's suppliers and partners may be impacted by the potential product launch.

Next Steps

• A pre-NDA meeting with the FDA is planned for Q4 2024.
• A pediatric study is scheduled to commence in Q4 2024.
• The company plans to submit an NDA to the FDA in Q1 2025.
• A full product launch is anticipated in Q1 2026, pending FDA approval.

Key Dates

Keywords

Anaphylm, epinephrine, oral allergy syndrome, OAS, sublingual film, pharmacokinetics, pharmacodynamics, FDA, NDA, allergy, anaphylaxis, clinical trial